CD274 and non-small cell lung carcinoma: Concurrently, numerous phase 3 clinical trials for advanced NSCLC, regardless of PD-L1 TPS, have reported significantly improved clinical outcomes in patients treated with combination therapy of ICI and chemotherapy (COMBO) compared to those treated with chemotherapy alone.